The number of CD34 ؉ cells has been described as the best parameter for predicting the quality of engraftment in peripheral blood progenitor cell (PBPC) transplantation in the early post-transplant period. In this study we have determined the optimal number of CD34 ؉ cells in order to maintain engraftment in the long term in a series of 100 patients receiving autologous PBPC transplantation. Based on our previous experience on the speed of early hematopoietic recovery, four subgroups of patients were established: patients infused less than 0.75 ؋ 10 6 /kg CD34 ؉ (n = 9), 0.75 to 1.25 (n = 24), 1.25 to 2.0 (n = 37) and more than 2.0 (n = 30). These groups were designated as low, intermediate-low, intermediate-high and high CD34 groups, respectively. Transitory loss of neutrophil engraftment was observed in 67%, 30%, 16% and 6% of patients in the four mentioned CD34 groups respectively, with statistically significant differences between the different groups. Significant differences were also observed between the low CD34 group and the rest of the groups as regards platelet and red blood cell transfusion requirements, fever episodes, days of hospitalization and antibiotic requirements throughout the first year. Our results show that the dose of CD34 ؉ cells influences engraftment also in the late post-transplant period, and correlates with transfusion and antibiotic requirements, fever episodes and days of hospitalization during the first year posttransplant.
The number of CD34 ϩ cells has been described as the best parameter for predicting the quality of the engraftment in peripheral blood progenitor cell (PBPC) transplantation. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] In several studies it has been related to the speed of hematopoietic recovery. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Furthermore, the infusion of an optimal number of CD34 ϩ cells has been associated with an economic benefit in terms of reducing the days of hospitalization, antibiotics and transfusion requirements. 17, 20 ever, all these studies have focused on the early posttransplant period and information regarding the impact of the number of CD34 ϩ cells in long-term follow-up has not yet been clearly defined in a large series of patients. 18 We have previously reported that a number of CD34 ϩ cells as low as 0.75 ϫ 10 6 CD34 ϩ /kg assures early engraftment in a reasonable number of days. 19 In the present study, we have first analyzed whether or not this minimal number of CD34 ϩ cells for early engraftment also assures late engraftment. In addition, we have searched for the optimal number of CD34 ϩ cells in order to reduce infections episodes, days of hospitalization, antibiotics and transfusion requirements in a long-term follow-up (365 days) in a series of 100 patients receiving autologous PBPC transplantation.
Materials and methods

Patients' characteristics and PBPC reinfused
One hundred cancer patients received high-dose therapy and PBPC transplant between August 1995 and June 1997. All patients signed an Institutional Approved Informed Consent. Fifty-one patients had breast cancer, 31 lymphomas, 15 multiple myeloma, and 3 other solid tumors. Conditioning regimens consisted of cyclophosphamide ϩ carboplatin ϩ thiotepa 20 in breast cancer, BEAM protocol 21 in lymphoma patients and melphalan or melphalan ϩ TBI 22 in multiple myeloma. All patients were followed for 1 year after progenitor cell infusion or from progenitor cell infusion to death. In all these patients, we have analyzed delayed loss of engraftment, infectious episodes, antibiotic requirements, days of hospitalization and requirements for platelet and red blood cell transfusions during this period. Four subgroups of patients were established according to the number of CD34 ϩ cells/kg reinfused, based on our previous experience of early hematopoietic recovery, 19 patients receiving less than 0.75 ϫ 10 6 CD34 ϩ cells/kg (n = 9); 0.75 to 1.25 (n = 24); 1.25 to 2.0 (n = 37) and more than 2.0 ϫ 10 6 CD34 ϩ cells/kg (n = 30). These groups were designated as low, intermediate-low, intermediate-high and high CD34 groups, respectively. The median CD34 ϩ cell dose infused was 1.56 ϫ 10 6 /kg (range: 0.39 to 10.44). In the low CD34 group, 4/9 patients were Hodgkin's disease, 3/9 had metastasic breast carcinoma, 1/9 had multiple myeloma and 1/9 non-Hodgkin's lymphoma. All these patients except one had received at least two different regimens of chemotherapy.
After 1 year of follow-up, 12 patients had died: nine of these deaths were related to disease progression, two related to infectious disease (without loss of engraftment) and one death related to lung hemorrhage (associated with loss of engraftment).
Immunofluorescence analysis
The absolute number of CD34 ϩ cells was measured in erythrocyte-lysed peripheral blood samples prior to initiating each apheresis as well as in the leukapheresis product. Cells were stained with an anti-CD34 monoclonal antibody (antiHPCA-2) conjugated with PE and analyzed by flow cytometry (FACScan, Becton Dickinson, San Jose, CA, USA) as previously described. 19, 23 In order to increase the sensitivity and specificity of the measurement, a two-step acquisition procedure was performed in every case: in the first step 20 000 events were acquired; in the FSC/SSC dot plot, granulocytes, monocytes and lymphocytes were selected eliminating debris and RBCs in order to calculate the percentage of nucleated cells. In the second acquisition step a total of 300 000 events was acquired to assure a low coefficient of variation for the measurement. 24 A side scatter/CD34-PE live gate was performed in which only cells with high intensity of PE fluorescence were selected; the cluster of CD34 ϩ cells was then selected among these events around the low-intermediate side scatter as we have already described. 19, 23 With this acquisition procedure, even at a very low percentage of CD34 ϩ cells, a cluster of events in this region is usually identified. 19, 23, 25 The proportion of CD34 ϩ cells was then calculated as follows: number of CD34 ϩ events selected in the second acquisition step ϫ 100/300 000 events ϫ % of nucleated cells obtained in the first acquisition step. Then the absolute count of PB CD34 ϩ cells/l was calculated by multiplying the proportion of CD34 ϩ cells by the WBC count.
Toxicity
Post-transplant complications were evaluated during the first 365 days after stem cell infusion. Late loss of engraftment was defined as a granulocyte count lower than 1.0 ϫ 10 9 /l and/or a platelet count lower than 20 ϫ 10 9 /l in patients who had previously reached these counts after PBPC transplant.
Transfusions of red blood cell units were performed when hemoglobin values decreased to less than 8.0 g/dl or above this limit when symptomatic anemia occurred. Platelets were transfused in cases of thrombocytopenia lower than 10 ϫ 10 9 /l or in cases of fever or hemorrhage with platelet counts lower than 20 ϫ 10 9 /l. All products were irradiated.
Antibiotic therapy was given for any clinical or microbiological infection, or for a persistent undocumented fever above 38°C. During the year post-transplant, patients were hospitalized due to infectious disease in case of severe clinical picture or when fever persisted more than 48 h after treatment with oral antibiotic therapy.
Statistical analysis
Descriptive analysis was performed using the SPSS software program (Chicago, IL, USA). Differences concerning infectious episodes, days of hospitalization and transfusion requirements between the different CD34 ϩ subgroups were analyzed using the Pearson chi-square, ANOVA and Student's t-tests. Non-parametric tests were used when needed. Statistically significant differences were considered when the P value was lower than 0.05.
The influence of diagnosis, previous chemotherapy and CD34 ϩ cell dose infused on late engraftment and late complications was studied in a multivariate analysis.
Results
Late hematopoietic engraftment and transfusion requirements according to CD34
ϩ cells dose reinfused (Table 1) . When we analyzed red blood cell transfusion unit requirements during the first year after PBPC transplant, we observed statistically significant differences between the low CD34 group and the other groups (P = 0.0003): patients in the low CD34 group required a mean of 6.8 units (95% CI: 1.96-11.81), while patients in the intermediate-low, intermediate-high and high CD34 groups required a mean of 3.33 units (95% CI: 2.51-4.15), 2.81 units (95% CI: 2.04-3.57) and 2.2 units (95% CI: 1.4-2.9), respectively (Table 1) .
Regarding platelet requirements, statistically significant differences were also observed between the low CD34 group (mean of 36.55 units) and the other groups (mean ranging from 16.41 to 27.12 units), (P = 0.0038) ( Table 1) .
Finally, upon considering CD34 ϩ cell dose as a dichotomous variable, it was found that up to a level of 2.2 and 2.4 ϫ 10 6 CD34 ϩ cells/kg, the higher the dose of CD34 ϩ cells infused the lower the red blood cell and platelet transfusional requirements, respectively. 
Relationship between infectious complications and the CD34 ϩ cells dose reinfused
During the period from day of discharge from transplant up to day ϩ365, 27% of patients developed at least one fever episode. Mean days of fever was significantly higher in the low CD34 group of patients (3.88 days, 95% CI: 0-7.8 days), as compared to those in the intermediate-low, intermediate-high and high CD34 groups: 1.37 days (95% CI: 0-2.7 days), 0.51 days (95% CI: 0-0.9) and 0.62 days (95% CI: 0-1.06), respectively (P = 0.0024). Periods of hospitalization due to fever episodes after transplant discharge were also significantly longer in patients receiving Ͻ0.75 ϫ 10 6 CD34 ϩ cells/kg (P = 0.018): a mean of 5.22 days of hospitalization in the low CD34 group vs 1.0 days in the intermediate-low group, 0.81 days in the intermediate-high group and 1.16 days in the high CD34 group. Moreover, when we consider total days of hospitalization (from day 0 to day ϩ365 post-transplant), those patients in the low CD34 group had a statistically significant longer duration of hospital stay as compared to the rest of the groups (P = 0.0066): a mean of 26 Requirements for antibiotics during the year post transplantation were again related to the CD34 ϩ cell dose infused: those patients in the low CD34 group required a mean of 10.77 days of antibiotic therapy during the period between discharge and day ϩ365, those in the intermediatelow group required 2.95 days, those in the intermediatehigh group 1.97 days and those in the high CD34 group required a mean of 2.76 days of antibiotics (P = 0.0028 upon comparing the low CD34 group and the rest of the groups) ( Table 2 ). As shown in Table 2 statistically significant differences were also observed in days of antibiotic therapy when we also include the early post-transplantation period (hospital stay from day 0 to discharge).
Finally, when we analyzed CD34 ϩ cell dose as a dichotomous variable, it was found that up to a level of 1.75 and 2.0 ϫ 10 6 CD34 ϩ cells/kg, the higher the dose of CD34 ϩ cells the lower the days of fever after discharge and of hospitalization, respectively.
Influence of other variables
The influence of diagnosis, previous chemotherapy and CD34 ϩ cell dose infused on late engraftment and late complications was studied in a multivariate analysis. It was found that the number of reinfused CD34 ϩ cells has an independent influence on all the parameters: transitory loss of neutrophil (P = 0.028) and platelet (P = 0.03) engraftment, RBC units (P = 0.03) and platelet units (P = 0.01) transfusion requirements, days of fever after discharge (P = 0.02), hospital stay after discharge (P = 0.01) and from day 0 to day 365 (P = 0.02), days of antibiotic therapy after discharge (P = 0.01) and from day 0 to day 365 (P = 0.01).
The influence of the other variables included in in the analysis is as follows: diagnosis of Hodgkin's disease influence on transitory loss of neutrophil engraftment (P = 0.024), RBC transfusion requirements (P = 0.009) and days of antibiotics after discharge (P = 0.03). The number of previous regimens of chemotherapy influenced hospital stay (P = 0.001) and days of antibiotics (P = 0.004) during the first year after transplantation.
Discussion
Measurement of CD34
ϩ cells appears to be the most precise method for predicting the quality of engraftment and the number of CD34 ϩ cells has been clearly related to the speed of hematopoietic recovery. 14, [17] [18] [19] 26 In contrast to the numerous studies devoted to investigating the correlation between the number of CD34 ϩ cells infused and early engraftment, 18, 19 little attention has been paid to late engraftment complications and no study has been so far reported in which the ideal threshold of CD34 ϩ cells to avoid late complications after transplantation 17, 26 is analyzed. As far as hematopoietic engraftment is concerned, after 1 year of follow-up, we have found that none of the patients infused more than 0.75 ϫ 10 6 /kg CD34 ϩ cells developed permanent loss of engraftment. Nevertheless, in 30% of patients infused 0.75 to 1.25 ϫ 10 6 CD34 ϩ cells/kg a transitory loss of engraftment was observed. It is important to
CD34
؉ cell dose in long-term engraftment after PBPC transplantation JA Pérez-Simón et al 1282 note that five out of these seven patients received less than 1.1 ϫ 10 6 CD34 ϩ cells/kg. These results would suggest that a minimum of 1.1 ϫ 10 6 CD34 ϩ cells/kg should be infused to assure a permanent hematopoietic engraftment. It is important to mention that usually higher values of CD34 ϩ cell dose have been recommended by other groups. 7, 8, 18, [26] [27] [28] Discrepancies are probably due to the method employed for their analysis. 11, 19, [22] [23] [24] It should be pointed out that for stabilized whole blood preparations containing relatively high numbers of CD34 ϩ cells, the protocol used in the present study, as regards staining of the sample largely overlaps with other commonly used methods, 29 the acquisition of high numbers of events (300 000) using a multidimensional gating strategy will provide a more accurate identification of the real CD34 ϩ cells as well as a more precise evaluation of their proportion within the sample. 30 The reproducibility of this method, and its ability to predict the speed of hematopoietic recovery and the early and late transfusional requirements, as well as the late complications after PBPC transplant, indicates that this is a reliable method for the assessment of progenitor cells.
Regarding factors which could influence on CD34 ϩ cell collection, it is clear that factors as underlying disease and previous chemotherapy are responsible for a poor CD34 ϩ cell collection.
Upon considering transfusional requirements after transplantation, our study shows that, as previously reported by other groups, 17 ,26 the infusion of high numbers of CD34 ϩ cells decreases transfusional requirements in the early posttransplant period. In the present study, we also demonstrate that this benefit is maintained in the long term. Thus, the group of patients receiving less than 0.75 ϫ 10 6 CD34 ϩ cells/kg required significantly more red blood cell and platelet transfusions as compared to the rest of patients. Nevertheless, differences did not reach statistical significance when the intermediate-low, intermediate-high and high CD34 groups are compared. Even more, benefit in terms of lower transfusional requirements disappeared over a threshold of Ͼ2.2 ϫ 10 6 CD34 ϩ cells/kg. This would suggest that the benefit of higher doses of CD34 ϩ cells reach maximum at the mentioned dose, which is in accordance with our previous data suggesting that to harvest above a certain number of CD34 ϩ cells/kg would not accelerate hematopoietic recovery. 19 Regarding days of hospital stay, Ketterer et al 26 have reported that high CD34 ϩ cell counts allowed a further shortening of the duration of hospitalization in the early post-transplantation period. In our study, we demonstrate that this association also applies to the late post-transplant period. Finally, the CD34 ϩ cell dose also influences the number of fever episodes and antibiotic requirements not only when we consider the early post-transplant period, but also after discharge from transplantation. This benefit would translate both into more safety for the patient and also significant cost saving.
In summary, our results show that to infuse over 0.75 ϫ 10 6 /kg CD34 ϩ cells guarantees early and late hematopoietic recovery, but in order to avoid transitory late loss of engraftment, a dose higher than 1.1 ϫ 10 6 /kg CD34 ϩ cells is desirable. Moreover, to infuse higher doses of progenitor cells decreases complications and transfusion requirements after PBPC transplantation even in the longterm follow-up and the ideal threshold to infuse would be around 2.2 ϫ 10 6 /kg CD34 ϩ cells. To infuse over this dose of CD34 ϩ cells does not lead to a significant increase of benefits after PBPC transplant.
